RxDoctor Payments Data

Alan Sweeney, MD

Internal Medicine · Lemoyne, PANPI 1518958917

Payments from drug & device makers

$1,096in general payments, 2019–2025

Across 59 payments — averaging $18.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$271
  • GSK$200
  • Shield Therapeutics Inc$83
  • Amgen$53
  • Paratek Pharmaceuticals, Inc.$52
  • Dexcom, Inc.$52
  • plus $386 from 15 others

What the payments were for

  • Food & beverage$1,096100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,096 in reported general payments places this provider in the 75th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$312,886
Medicare patients
773
Services billed
4,807

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban129$136,274
JanuviaSitagliptin Phosphate59$62,589
JardianceEmpagliflozin39$53,664
MounjaroTirzepatide35$36,834
TrulicityDulaglutide17$33,285
XareltoRivaroxaban32$32,039
MyrbetriqMirabegron15$11,709
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$10,568
Metoprolol Succinate296$8,679
Aimovig AutoinjectorErenumab-Aooe11$7,976
RestasisCyclosporine11$7,540
Breo ElliptaFluticasone/Vilanterol18$7,403
ArexvyRsvpref3 Antigen/As01e/Pf23$7,351
Atorvastatin Calcium431$6,810
Rosuvastatin Calcium249$6,017

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$25$136,274129 claims
Lilly USA, LLCMounjaro, Trulicity$33$70,11952 claims
MerckJanuvia$38$62,58959 claims
Johnson & JohnsonXarelto$12$32,03932 claims
GSKTrelegy Ellipta, Breo Ellipta, Arexvy$200$25,32258 claims
Astellas Pharma US IncMyrbetriq$43$11,70915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Lemoyne

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →